消化

订阅

MedSci主页 / 所有栏目 / 消化

加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌

2019-05-23 不详 网络

Ogivri曲妥珠单抗生物仿制药加拿大卫生部
关注

Mylan和Biocon公司近日宣布，加拿大卫生部已批准Mylan与Biocon共同开发的Ogivri™（曲妥珠单抗生物仿制药）用于治疗HER2过度表达的乳腺癌和转移性胃癌患者。

Mylan和Biocon公司近日宣布，加拿大卫生部已批准Mylan与Biocon共同开发的Ogivri™（曲妥珠单抗生物仿制药）用于治疗HER2过度表达的乳腺癌和转移性胃癌患者。

Ogivri是加拿大批准的第一个曲妥珠单抗生物仿制药，也是市场上批准的Mylan和Biocon联合投资组合中的第二个生物仿制药。Mylan计划将在本季度推出该产品，Mylan的首席商务官Tony Mauro评论说：“作为生物仿制药开发的全球领导者，我们很高兴Ogivri获得加拿大卫生部的批准，我们有机会将这一重要的治疗方案推向加拿大市场。我们期待继续与加拿大卫生药品和技术机构（CADTH）和泛加拿大制药联盟（pCPA）进行医保报销讨论，以确保患者能够获得Ogivri”。


原始出处：

http://www.firstwordpharma.com/node/1642569#axzz5okQFj1Sv

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771542, encodeId=6f241e7154265, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Sat Jun 15 10:11:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Wed Apr 29 06:11:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269555, encodeId=9255126955587, content=<a href='/topic/show?id=ae2e132e6c7' target=_blank style='color:#2F92EE;'>#Ogivri#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13276, encryptionId=ae2e132e6c7, topicName=Ogivri)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312612, encodeId=7c4f131261287, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443348, encodeId=70ea14433481a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585654, encodeId=531a1585654eb, content=<a href='/topic/show?id=234560231be' target=_blank style='color:#2F92EE;'>#曲妥珠单抗生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60231, encryptionId=234560231be, topicName=曲妥珠单抗生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dfb17256974, createdName=李研东, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-06-15 rebeccajiejie

    #加拿大卫生部#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1771542, encodeId=6f241e7154265, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Sat Jun 15 10:11:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Wed Apr 29 06:11:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269555, encodeId=9255126955587, content=<a href='/topic/show?id=ae2e132e6c7' target=_blank style='color:#2F92EE;'>#Ogivri#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13276, encryptionId=ae2e132e6c7, topicName=Ogivri)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312612, encodeId=7c4f131261287, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443348, encodeId=70ea14433481a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585654, encodeId=531a1585654eb, content=<a href='/topic/show?id=234560231be' target=_blank style='color:#2F92EE;'>#曲妥珠单抗生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60231, encryptionId=234560231be, topicName=曲妥珠单抗生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dfb17256974, createdName=李研东, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2020-04-29 linlin2320

    #曲妥珠#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1771542, encodeId=6f241e7154265, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Sat Jun 15 10:11:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Wed Apr 29 06:11:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269555, encodeId=9255126955587, content=<a href='/topic/show?id=ae2e132e6c7' target=_blank style='color:#2F92EE;'>#Ogivri#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13276, encryptionId=ae2e132e6c7, topicName=Ogivri)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312612, encodeId=7c4f131261287, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443348, encodeId=70ea14433481a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585654, encodeId=531a1585654eb, content=<a href='/topic/show?id=234560231be' target=_blank style='color:#2F92EE;'>#曲妥珠单抗生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60231, encryptionId=234560231be, topicName=曲妥珠单抗生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dfb17256974, createdName=李研东, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-25 drwjr

    #仿制药#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1771542, encodeId=6f241e7154265, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Sat Jun 15 10:11:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Wed Apr 29 06:11:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269555, encodeId=9255126955587, content=<a href='/topic/show?id=ae2e132e6c7' target=_blank style='color:#2F92EE;'>#Ogivri#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13276, encryptionId=ae2e132e6c7, topicName=Ogivri)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312612, encodeId=7c4f131261287, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443348, encodeId=70ea14433481a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585654, encodeId=531a1585654eb, content=<a href='/topic/show?id=234560231be' target=_blank style='color:#2F92EE;'>#曲妥珠单抗生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60231, encryptionId=234560231be, topicName=曲妥珠单抗生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dfb17256974, createdName=李研东, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-25 daviiliu

    #Ogivri#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1771542, encodeId=6f241e7154265, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Sat Jun 15 10:11:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Wed Apr 29 06:11:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269555, encodeId=9255126955587, content=<a href='/topic/show?id=ae2e132e6c7' target=_blank style='color:#2F92EE;'>#Ogivri#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13276, encryptionId=ae2e132e6c7, topicName=Ogivri)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312612, encodeId=7c4f131261287, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443348, encodeId=70ea14433481a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585654, encodeId=531a1585654eb, content=<a href='/topic/show?id=234560231be' target=_blank style='color:#2F92EE;'>#曲妥珠单抗生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60231, encryptionId=234560231be, topicName=曲妥珠单抗生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dfb17256974, createdName=李研东, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-25 闆锋旦

    #HER2阳性#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1771542, encodeId=6f241e7154265, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Sat Jun 15 10:11:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Wed Apr 29 06:11:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269555, encodeId=9255126955587, content=<a href='/topic/show?id=ae2e132e6c7' target=_blank style='color:#2F92EE;'>#Ogivri#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13276, encryptionId=ae2e132e6c7, topicName=Ogivri)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312612, encodeId=7c4f131261287, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443348, encodeId=70ea14433481a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585654, encodeId=531a1585654eb, content=<a href='/topic/show?id=234560231be' target=_blank style='color:#2F92EE;'>#曲妥珠单抗生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60231, encryptionId=234560231be, topicName=曲妥珠单抗生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dfb17256974, createdName=李研东, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-25 shanyongle

    #加拿大#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1771542, encodeId=6f241e7154265, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Sat Jun 15 10:11:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Wed Apr 29 06:11:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269555, encodeId=9255126955587, content=<a href='/topic/show?id=ae2e132e6c7' target=_blank style='color:#2F92EE;'>#Ogivri#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13276, encryptionId=ae2e132e6c7, topicName=Ogivri)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312612, encodeId=7c4f131261287, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443348, encodeId=70ea14433481a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585654, encodeId=531a1585654eb, content=<a href='/topic/show?id=234560231be' target=_blank style='color:#2F92EE;'>#曲妥珠单抗生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60231, encryptionId=234560231be, topicName=曲妥珠单抗生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dfb17256974, createdName=李研东, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-25 grace5701

    #生物仿制药#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1771542, encodeId=6f241e7154265, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Sat Jun 15 10:11:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Wed Apr 29 06:11:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269555, encodeId=9255126955587, content=<a href='/topic/show?id=ae2e132e6c7' target=_blank style='color:#2F92EE;'>#Ogivri#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13276, encryptionId=ae2e132e6c7, topicName=Ogivri)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312612, encodeId=7c4f131261287, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443348, encodeId=70ea14433481a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585654, encodeId=531a1585654eb, content=<a href='/topic/show?id=234560231be' target=_blank style='color:#2F92EE;'>#曲妥珠单抗生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60231, encryptionId=234560231be, topicName=曲妥珠单抗生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dfb17256974, createdName=李研东, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-25 12498e67m29暂无昵称

    #卫生部#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1771542, encodeId=6f241e7154265, content=<a href='/topic/show?id=213033009ec' target=_blank style='color:#2F92EE;'>#加拿大卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33009, encryptionId=213033009ec, topicName=加拿大卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58fa38314021, createdName=rebeccajiejie, createdTime=Sat Jun 15 10:11:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Wed Apr 29 06:11:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261492, encodeId=52e41261492cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269555, encodeId=9255126955587, content=<a href='/topic/show?id=ae2e132e6c7' target=_blank style='color:#2F92EE;'>#Ogivri#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13276, encryptionId=ae2e132e6c7, topicName=Ogivri)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308535, encodeId=237d1308535c9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312612, encodeId=7c4f131261287, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69188, encryptionId=a3996918811, topicName=生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfb42911806, createdName=grace5701, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443348, encodeId=70ea14433481a, content=<a href='/topic/show?id=d2d0366e60a' target=_blank style='color:#2F92EE;'>#卫生部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36676, encryptionId=d2d0366e60a, topicName=卫生部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=538e5060306, createdName=12498e67m29暂无昵称, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585654, encodeId=531a1585654eb, content=<a href='/topic/show?id=234560231be' target=_blank style='color:#2F92EE;'>#曲妥珠单抗生物仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60231, encryptionId=234560231be, topicName=曲妥珠单抗生物仿制药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dfb17256974, createdName=李研东, createdTime=Sat May 25 11:11:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-25 李研东

    #曲妥珠单抗生物仿制药#

    0

相关资讯

CHMP对Mylan和Biocon的曲妥珠单抗生物类似物Ogivri持积极意见

Mylan制药和Biocon制药近日宣布，欧洲药品管理局委员会人用药品（CHMP）发表了积极意见，建议批准Ogivri（罗氏曲妥珠单抗的生物类似物）。